Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Lynette Denny GCOB (Silver)

    University of Cape Town
    Cape Town, South Africa

    Lynette Denny is a gynaecological oncologist and professor of special projects at the Department of Obstetrics and Gynaecology, Faculty of Health Sciences at the University of Cape Town, South Africa. Prof. Denny has worked in the field of cervical cancer prevention in low-resource settings in collaboration with colleagues from Columbia University, New York, since 1995. read more

    Prof. Denny and her research group pioneered the search for alternative protocols for the prevention of cervical cancer in community-based research sites in the townships just outside Cape Town. Since then, Prof. Denny and her group have had extensive experience in cervical cancer prevention, including three cross-sectional studies comparing different screening tests, a prophylactic human papillomavirus (HPV) vaccine trial in human immunodeficiency virus-positive women and a therapeutic vaccine trial in HPV-negative women. Prof. Denny and her group are currently engaged in a USA National Cancer Institute-funded trial evaluating an HPV screen-and-treat approach.

    Prof. Denny has been the director of the South African Medical Research Council Gynaecological Cancer Research Centre for the past 7 years. She was the chair and professor of obstetrics and gynaecology at Groote Schuur Hospital/University of Cape Town from 2013–2022. In November 2021, she was awarded the Grand Counsellor of the Baobab in silver by the president of South Africa for ‘distinguished service’ to South Africa. In November 2022, she was awarded the Lifetime Achievement Award by the South African Society of Obstetricians and Gynaecologists.

    Prof. Lynette Denny discloses: Advisory board or panel fees from Vaccitech. Other financial or material support (royalties, patent, etc.) from UptoDate. Speaker’s bureau fees from Roche Diagnostics.
    Prof. Eduardo Franco OC

    McGill University
    Montreal, Canada

    Eduardo Franco is a James McGill professor and chairman of the Department of Oncology, and director of the Division of Cancer Epidemiology at McGill University, Montreal, Canada. Since 1985, Prof. Franco has conducted epidemiological research into cancer causes and prevention, and means to improve patient survival. read more

    Prof. Franco is an Officer of the Order of Canada, and a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences. He is also a foreign member of the Brazilian Academy of Sciences. Prof. Franco has received the Distinguished Service to Cancer Research Award from the Canadian Cancer Research Alliance; lifetime achievement awards from the American Society for Colposcopy and Cervical Pathology, and the International Papillomavirus Society; the Women in US Government’s Leadership Award; the O. Harold Warwick Prize from the Canadian Cancer Society; the Geoffrey R. Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics; the Dr Chew Wei Memorial Prize in Cancer Research from the University of British Columbia; and the McLaughlin-Gallie visiting professorship from the Royal College of Physicians and Surgeons of Canada. Prof. Franco is the editor-in-chief of the Journal of the National Cancer Institute, editor-in-chief emeritus of Preventive Medicine and a senior editor of eLife. He has served on the editorial boards of several top-tier journals in oncology and epidemiology.

    Prof. Eduardo Franco discloses: Advisory board or panel fees from BD Biosciences, Roche, Merck and PathoVax. Grants/research support from Merck. Other financial or material support (royalties, patent, etc.) for a registered patent entitled “DNA methylation markers for early detection of cervical cancer”.
    Prof. Daniel Kelly OBE

    European Cancer Organisation,
    HPV Action Network
    Cardiff, UK

    Daniel Kelly has co-chaired the HPV Action Network of the European Cancer Organisation since 2019, where he was a former board member. Prof. Kelly is also the Royal College of Nursing chair of nursing research at the School of Healthcare Sciences, Cardiff University, UK, a position that he has held since 2011. read more

    Prof. Kelly’s career-long interest has been in cancer care research and education, and cancer prevention, particularly the potential of human papillomavirus (HPV) vaccination and screening to protect young people from cancer. Prof. Kelly was awarded an Officer of the Order of the British Empire from the late Queen Elizabeth II in 2021 for his contribution to research and education in cancer care. Prof. Kelly is a former president of the European Oncology Nursing Society, and is a fellow of the Royal College of Nursing of the UK. He is currently a visiting professor at Edinburgh University, University College London and Oxford Brookes University. Prof. Kelly is also a trustee at St Christopher’s Hospice London and a Public Governor at King’s College London NHS Foundation Trust. Prof. Kelly has published over 250 papers and has contributed to many international conferences, including presenting the case for HPV to be included in the Beating Cancer Plan in the European Parliament.

    Prof. Daniel Kelly has no financial interests/relationships or affiliations in relation to this activity.
    touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Sexually Transmitted Infections

    An Introduction to Sexually Transmitted Infections

    Sexually transmitted infections (STIs) affect millions of people worldwide; approximately 1 in 5 adults in the US had an STI in 2018. More than 30 bacteria, viruses and bacteria can be transmitted through sexual contact. Many bacterial infections can be treated effectively using ceftriaxone, doxycycline, penicillin, moxifloxacin, and the nitroimidazoles for gonorrhoea, chlamydia, syphilis, Mycoplasma genitalium, and trichomoniasis, respectively, although antibiotic resistance has reduced treatment options for gonorrhoea. Viral STIs are currently incurable: hepatitis B, herpes simplex virus, HIV and human papillomavirus, though effective vaccines are available for hepatitis B and HPV, there are several vaccine candidates for HIV and herpes are in clinical development.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal, touchREVIEWS in Infectious Diseases, provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Sexually Transmitted Infections Content

    Vaccines, Sexually Transmitted Infections, Viral Infections
    Watch Time: 35 mins
    touchPANEL DISCUSSION
    Preventing HPV-associated cancer by maximizing vaccine uptake
    CE/CME ACCREDITED Prof. Lynette Denny GCOB (Silver), Prof. Eduardo Franco OC, Prof. Daniel Kelly OBE

    Watch three experts discuss the importance of HPV vaccination in preventing HPV-associated cancers, and how to maximize vaccine uptake

    Learning objectives
    Learning Objectives
    • Illustrate the importance of vaccinating children and adolescents against HPV to prevent cancer in adulthood
    • Describe recent guidelines and best practices for HPV vaccine eligibility and administration
    • Appraise the barriers to HPV vaccine uptake in different populations and how they may be overcome
    HIV, Sexually Transmitted Infections, Viral Infections
    Watch Time: 38 mins
    touchPANEL DISCUSSION
    Shaping ART around individual needs: Maximizing adherence and quality of life
    Prof. Jens Lundgren, Prof. Marta Boffito, Ms Angelina Namiba Translations available:

    Watch three experts discuss how to optimize antiretroviral therapy for people living with HIV through an individualized approach to care

    Learning objectives
    Learning Objectives
    • Assess the individual needs of newly diagnosed people living with HIV who are initiating ART
    • Apply shared decision making to select the most appropriate first-line ART regimen for people living with HIV
    • Use relevant monitoring strategies for people living with HIV receiving ART, to revise treatment regimen in line with changes in life and preferences
    Sexually Transmitted Infections, Viral Infections
    Developed by Touch
    Christoph Boesecke: Monkeypox outbreak – Diagnosis, symptoms and guidelines

    Since 13 May 2022, rising cases of monkeypox have been reported to the World Health Organization (WHO) across the United Kingdom and Europe, and even some cases in the US and Canada. Based on currently available information, cases have mainly but not exclusively been identified amongst men who have sex with men seeking care in […]

    Sexually Transmitted Infections, Bacterial Infections
    Olivia Van Gerwen, MD, MPH, International Women’s Day 2022: Perspectives from a Working Mother and Sexual Health and Infectious Diseases Specialist

    As part of International Women’s Day, Dr Olivia Van Gerwen (The University of Alabama at Birmingham, Division of Infectious Diseases, Birmingham, AL, USA) one of touchINFECTIOUS DISEASES Editorial board members, joins us to discuss her impressive career highlights, and her own experiences of building her career alongside raising a family and overcoming a medical illness. […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72